WO2010014622A3 - In vitro model for modulating the blood brain barrier and methods of screening - Google Patents
In vitro model for modulating the blood brain barrier and methods of screening Download PDFInfo
- Publication number
- WO2010014622A3 WO2010014622A3 PCT/US2009/051978 US2009051978W WO2010014622A3 WO 2010014622 A3 WO2010014622 A3 WO 2010014622A3 US 2009051978 W US2009051978 W US 2009051978W WO 2010014622 A3 WO2010014622 A3 WO 2010014622A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brain barrier
- methods
- screening
- blood brain
- modulating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Abstract
An in vitro blood brain barrier (BBB) model is provided as well as in vitro methods for screening molecules for the ability to pass through the BBB or the ability to tighten the endothelial cell junctions in the BBB.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8422508P | 2008-07-28 | 2008-07-28 | |
US61/084,225 | 2008-07-28 | ||
US8449208P | 2008-07-29 | 2008-07-29 | |
US61/084,492 | 2008-07-29 | ||
US19311608P | 2008-10-29 | 2008-10-29 | |
US61/193,116 | 2008-10-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010014622A2 WO2010014622A2 (en) | 2010-02-04 |
WO2010014622A3 true WO2010014622A3 (en) | 2010-05-06 |
Family
ID=41610935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/051978 WO2010014622A2 (en) | 2008-07-28 | 2009-07-28 | In vitro model for modulating the blood brain barrier and methods of screening |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010014622A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2770223T3 (en) | 2016-01-29 | 2020-07-01 | Hoffmann La Roche | Electrochemiluminescence procedure and apparatus for detecting an analyte in a liquid sample |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
JP2020508049A (en) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | Engineered transferrin receptor binding polypeptide |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
CN114107386B (en) * | 2021-11-29 | 2024-02-02 | 中国人民解放军军事科学院军事医学研究院 | Method for preparing mouse model with blood brain barrier defect |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049709A1 (en) * | 2000-01-03 | 2001-07-12 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
US6403325B1 (en) * | 1997-06-30 | 2002-06-11 | The Brigham And Women's Hospital, Inc. | Methods and compounds for treating alzheimer's disease |
WO2005063966A2 (en) * | 2003-12-23 | 2005-07-14 | Axaron Bioscience Ag | Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells |
-
2009
- 2009-07-28 WO PCT/US2009/051978 patent/WO2010014622A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403325B1 (en) * | 1997-06-30 | 2002-06-11 | The Brigham And Women's Hospital, Inc. | Methods and compounds for treating alzheimer's disease |
WO2001049709A1 (en) * | 2000-01-03 | 2001-07-12 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
WO2005063966A2 (en) * | 2003-12-23 | 2005-07-14 | Axaron Bioscience Ag | Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells |
Also Published As
Publication number | Publication date |
---|---|
WO2010014622A2 (en) | 2010-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008118392A3 (en) | Synthetic cell platforms and methods of use thereof | |
WO2010002540A3 (en) | Activation and monitoring of cellular transmembrane potentials | |
WO2008148105A8 (en) | Endometrial stem cells and methods of making and using same | |
EP2286902A4 (en) | Separation membrane, method of producing the same and separation membrane module using the separation membrane | |
EP1988152A4 (en) | Cell culture construct, cell culture container, construct having spheroid, container having spheroid and method of producing the same | |
EP2727998A3 (en) | Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells | |
AU325506S (en) | Headphones | |
WO2009114601A3 (en) | Preparation of lenalidomide | |
ZA201102488B (en) | Methods for cultivating cells, propagating and purifying viruses | |
BRPI0810744A2 (en) | ABSORBENT OXYGEN MOLECULES, OBJECTS CONTAINING THEM, AND METHODS OF USE | |
EP2215126A4 (en) | Compositions and methods to modulate cell membrane resealing | |
SG196784A1 (en) | Stem cell cultures | |
AU325844S (en) | Filter package | |
WO2011011366A3 (en) | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof | |
WO2012088029A3 (en) | Secure application attestation using dynamic measurement kernels | |
WO2007097993A3 (en) | Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor | |
WO2007120302A3 (en) | Liquid crystalline substrates for culturing cells | |
WO2012076985A8 (en) | Granzyme b inhibitor compositions, methods and uses for promoting wound healing | |
EP2352467A4 (en) | Fluid collection system and methods of using same | |
WO2011066288A3 (en) | Systems and methods for enhancing growth of carbon-based nanostructures | |
WO2010062911A3 (en) | Compositions and methods of functionally enhanced in vitro cell culture system | |
WO2010014622A3 (en) | In vitro model for modulating the blood brain barrier and methods of screening | |
AU319982S (en) | Cross connect block | |
EP2382464A4 (en) | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification | |
WO2011119986A3 (en) | Methods for culturing and analyzing cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09803490 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09803490 Country of ref document: EP Kind code of ref document: A2 |